Transforming cancer treatment with novel targets
Sathgen Therapeutics – developing innovative oncology therapies for difficult-to-treat cancers
Welcome to Sathgen Therapeutics
At Sathgen Therapeutics, we use an integrated approach to study and target the difficult-to-treat cancers. Hence, our solution involves examining the disease as a complex system as opposed to a one-gene-one-disease remedy. In addition to targeting cancers, our drug can also treat viral infections such as COVID-19.
Strong Financial and Technical Support
Sathgen Therapeutics has strong financial and technical support to help achieve its goals. We are backed by Godavari Biorefineries Limited (GBL), and linked to the Somaiya Group, which is actively involved in healthcare and education. Our CRO partner, Clinexel, provides expertise in early-stage clinical development and capabilities for global clinical development. With the support of our partners, we are confident that we can bring new and innovative therapies to patients in need.
Initiation of phase I trials of MSP008-22 in patients with advanced solid tumors in February 2023.
Completion of the dosing of the first cohort of patients in the phase I clinical trial of MSP008-22 in June 2023.
Initiation of phase I trials of MSP008-22 in healthy individuals in April 2023.
Completion of the dosing of the first two cohorts of healthy volunteers in the phase I clinical trial of MSP008-22 in July 2023.
Preclinical Studies (Oncology):
Xenograft studies with triple negative breast cancer cells show tumor growth inhibition upon single arm MSP008-22 or in combination with standard-of-care chemotherapy, Carboplatin.
MSP008-22 improves the efficacy and lowers toxicity of another standard-of-care chemotherapy, Cisplatin, as shown by decreased IC50.
MSP008-22 shows excellent safety profile in pre-clinical models including induced human blood lymphocytes.
MSP008-22 also shows anti-stem cell and anti-metastatic efficacy in breast and prostate cancer models, in vitro.
Preclinical Studies (Anti-Viral):
Treatment with MSP008-22, both post-infection or prophylactic, reduces the SARS-CoV-2 viral load, and COVID-19-asscoiated Pneumonitis, alveolar injury, and inflammation score.
MSP008-22 inhibits viral replication to the same extent as the anti-viral, Remdesivir.
MSP008-22 shows anti-SARS-CoV-2 potential as observed in cytopathic assays, comparable to Remdesivir.
Sathgen Therapeutics is a clinical-stage biotech company working on bringing the first-in-class and best-in-class drugs ensuring novel treatments for difficult-to-treat cancers and potentially viral infections.